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Abstract
Introduction Neuronal antibodies can cause encephalopathy syndromes often presenting with subacute cognitive impair-
ment, sometimes resembling neurodegenerative dementias.
Methods We searched Medline and Embase for studies reporting associations between neuronal surface antibodies in all-
cause dementia versus controls. Random-effects meta-analysis was used to pool adjusted estimates across studies.
Results Six studies were included, all reporting frequency of serum NMDAR antibodies in dementia with four also reporting 
frequency in atypical dementias. Both IgG [OR = 8.09 (1.51; 56.85), p = 0.036] and IgA/IgM NMDAR antibodies [OR = 42.48 
(11.39; 158.52), p < 0.001] were associated with atypical dementia, but neither were associated with all-cause dementia.
Discussion In the first meta-analysis to explore this literature, serum IgG and IgA/IgM NMDAR antibodies were significantly 
more common in atypical dementias. However, methodological issues and small-sample sizes necessitate caution interpreting 
this result. Further studies measuring both serum and CSF antibodies are needed to investigate the role of neuronal antibod-
ies in dementia, since evidence of pathogenicity in even a subset of patients could pave the way for novel treatment options.
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Abbreviations
NMDAR  N-Methyl-d-aspartate receptor
LGI1  Leucine-rich glioma inactivated 1
CASPR2  Contactin-associated protein 2
AMPAR  α-Amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor
GABA  Gamma-aminobutyric acid
GAD  Glutamic acid decarboxylase
Introduction
The last decade has witnessed a rapid expansion in the 
description of central nervous system diseases associated 
with autoantibodies targeting neuronal and glial cell surface 
antigens. While the cascade of downstream effects has yet to 
be fully elucidated for many such autoantibodies, it is likely 
that their antigen-specificity determines their functional or 
pathogenic effects [1]. Autoimmune encephalitis denotes a 
group of central nervous system disorders associated with 
brain-directed autoantibodies with characteristic clinical 
syndromes. Most common is N-methyl-D-aspartate receptor 
(NMDAR) antibody encephalitis, in which IgG antibodies to 
the NR1 subunit of the NMDAR cause receptor internalisa-
tion, dynamic disorganisation of the NMDAR at the syn-
apse, and reduced NMDAR-related excitatory post-synaptic 
potentials [2–4]. The associated syndrome is well described, 
featuring prominent neuropsychiatric symptoms and cog-
nitive impairment with memory, attentional, and executive 
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deficits evident alongside movement disorder, seizures, and 
dysautonomia [5]. Cognitive impairment is a central fea-
ture of most of the autoimmune encephalitides though vari-
ation is seen in the affected cognitive domains. In LGI1 and 
CASPR2 encephalitis, antibodies bind to accessory proteins 
on voltage-gated potassium channels, typically causing diso-
rientation, confusion, and impairments in autobiographical 
memory [6]. In NMDAR encephalitis, cognitive deficits 
can persist for years after the initial insult and, in the acute 
phase, are often more pronounced in older adults [7, 8].
Neuronal surface autoantibodies have also been detected 
in patient populations outside the context of encephalitis, 
and particularly for IgA/IgM NMDAR antibodies, seroprev-
alence appears to be greater in older populations, although 
the clinical consequences of this are not yet known [9, 10]. 
The clinical profile of antibody-mediated cognitive impair-
ment has led to particular interest in the potential patho-
genicity of neuronal autoantibodies in neurodegenerative 
dementias. This is especially pertinent given the increas-
ing evidence supporting an autoimmune aetiology in many 
neurodegenerative dementias: Alzheimer’s disease is signifi-
cantly more common in most types of autoimmune disease, 
and genome-wide association studies have demonstrated 
numerous shared loci between Parkinson’s disease and auto-
immunity [11, 12]. Furthermore, functional autoantibodies 
have recently been suggested to play a causative role in the 
pathogenesis of Alzheimer’s disease [13]. Antibodies to a 
range of endogenous receptors have also been associated 
with increased mortality and neuropsychiatric symptoms in 
Alzheimer’s disease [14].
Given the evidence associating NMDAR hypofunction 
with cognitive decline in ageing, NMDAR antibodies could 
also be a promising focus [15]. Indeed, there are numerous 
cases of autoantibody-mediated, immunotherapy-responsive 
dementias which mimic primary neurodegenerative demen-
tias [16–18]. Furthermore, IgA NMDAR antibodies have 
been associated with ‘atypical dementia’ in older adults, 
characterised by a slowly progressive cognitive impairment 
which is reversible with immunotherapy [19]. While all 
NMDAR antibody isotypes show potential pathogenicity 
in vitro [20], distinction must be made between the encepha-
litogenic IgG isotype and the IgA and IgM isotypes which 
are of uncertain clinical relevance, but have been associated 
with cognitive impairment outside the context of encephali-
tis [21]. In addition, IgLON5 antibodies are associated with 
neuronal accumulation of hyperphosphorylated tau concur-
rent with the neuronal loss and gliosis typical of neurode-
generative disease [22].
Recently, the term ‘autoimmune dementia’ has been 
proposed to describe patients with a subacute cogni-
tive impairment which is reversible with immunotherapy 
[23]. While the prevalence of this condition is currently 
unclear, in a study of 56 patients initially diagnosed with 
a neurodegenerative or prion disorder, immunotherapy led 
to improvements across cognitive domains in a third of the 
patients [17]. This is of particular interest given the frustrat-
ing lack of progress that has been made to date with other 
disease modifying therapies in dementia. Indeed, identifying 
a pathogenic link between neuronal antibodies and cognitive 
decline in even a subset of patients with dementia could offer 
the potential of transformational new treatment options.
However, despite growing interest in the role of neu-
ronal antibodies in dementia, to our knowledge, there have 
been no attempts to systematically appraise the extant lit-
erature. We therefore conducted a systematic review and 
meta-analysis which aimed to (1) systematically appraise 
studies comparing frequency of neuronal autoantibodies 
(NMDAR, AMPAR,  GABAAR, GABABR, GAD, LGI1, and 
CASPR2) in patients with a primary diagnosis of dementia 
with healthy controls and (2) determine the magnitude and 
consistency of effects using meta-analytic techniques.
Methods
The protocol was registered on PROSPERO (registration 
number: CRD42018115200) and reported according to the 
Meta-Analysis of Observational Studies in Epidemiology 
(MOOSE) guidelines [24].
Search strategy
Embase, Ovid  MEDLINE® and Epub Ahead of Print, 
In-Process & Other Non-Indexed Citations, Daily and 
 Versions® were searched for articles published up to July 
2019. We used the search terms: (dementia OR alzheimer* 
OR fad OR lewy bod* OR frontotemporal OR ftd OR pro-
gressive supranuclear palsy OR psp OR primary progres-
sive aphasia OR ppa OR vascular OR korsakoff* OR pick*) 
AND (antibod* OR auto-antibod* OR autoantibod*) AND 
(n-methyl-d-aspartate OR nmda OR nmdar OR ampa OR 
ampar OR glutamate OR glur OR gaba OR potassium chan-
nel OR caspr2 OR lgi1 OR vgk* OR dppx OR d2r). The 
search was restricted to studies published in English. We 
included studies published in peer reviewed journals, while 
conference reports were excluded. Bibliographies of stud-
ies and reviews were searched manually for further eligible 
articles.
Study selection
Eligible articles were observational studies including at least 
ten participants with what we here denote a dementia syn-
drome: Alzheimer’s disease (AD) including familial Alz-
heimer’s disease (FAD), vascular dementia (VD), dementia 
with Lewy bodies (DLB), frontotemporal dementia (FTD) 
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with primary progressive aphasia (PPA) and Pick’s disease 
inclusive, progressive supranuclear palsy (PSP), and Kor-
sakoff’s syndrome, which performed assays for antibodies 
against anti-neuronal antigens and reported seropositivity 
or serum titres and included a healthy comparison group. 
The results were screened independently by two medically 
trained reviewers (A. McK and L.L.G.) who reached a con-
sensus on potentially eligible articles. When study cohorts 
overlapped, only the larger was included.
Data collection
Data were extracted independently by two reviewers (A. 
McK and L.L.G), who were not blinded to author names, 
journals, or institutions. Data extraction included: study 
recruitment procedure, description of participant groups and 
exclusion criteria, demographics, antibody assay methods 
(immunostaining methods, blinding, target antigen, antibody 
isotype, and seropositive threshold), and assay results.
Assessment of studies
Study quality was assessed independently by two reviewers 
(A. McK and L.L.G), using an adapted version of the New-
castle Ottawa Scale (NOS), a quality assessment tool for 
case–control studies. Discrepancies in quality ratings were 
resolved by a third researcher (A.E.C). The NOS addresses 
eight areas including: participant selection, case definition, 
matching, and exposure. These were modified as appropri-
ate for our analysis, giving ten modified items, which were 
rated for each study. Studies were scored 0 or 1 for eight of 
the ten items, and scored 0, 1, or 2 for two items, giving a 
maximum quality score of 12.
Statistical analysis
Statistical analyses were conducted using Stata version 15. 
Meta-analyses were performed to compare antibody pres-
ence in each dementia group (all-cause, typical, and atypical) 
with healthy controls. As we suspected that the true effect 
might vary across studies (owing to differences in dementia 
groups examined), random-effects models were employed 
for all analyses with inverse weighting applied [25]. We had 
originally intended to include all neuronal autoantibodies 
in the analysis. However, given that the search only identi-
fied one study quantifying the prevalence of autoantibodies 
other than NMDAR antibodies in dementia syndromes, we 
subsequently restricted our analysis to NMDAR antibodies. 
For NMDAR antibodies, the two outcome measures were 
seropositivity for IgG NMDAR antibodies and separately 
for IgA/IgM NMDAR antibodies combined. These antibody 
isotypes were assessed separately on the basis that their 
respective clinical implications are suspected to differ [26]. 
Statistically significant heterogeneity was determined via the 
Cochran Q statistic, the I2 statistic (estimating the percent-
age of the variability in odds ratios due to heterogeneity) 
was also calculated and categorised as likely ‘unimportant’ 
(0–40%), ‘moderate’ (30–60%), ‘substantial’ (50–90%), or 
‘considerable’ (75–100%) depending on the magnitude/
direction of effects and statistical significance of heteroge-
neity [27]. Exploratory meta-regression analyses were also 
performed to examine the relationship between study quality 
(NOS score) and effect sizes.
Results
Search strategy
Once duplicates were removed, our search returned 568 
results (see Fig. 1). After exclusion of conference reports 
and non-English language papers, abstracts were screened 
for 329 papers. Additional duplicates, animal studies and 
case reports were then excluded. For the remaining 17 stud-
ies, the full-text was assessed for eligibility. Nine further 
studies were then excluded due to inadequate definition of 
dementia syndromes, reporting exclusively seropositive 
patients, not reporting seropositivity in dementia patients 
or not testing the neuronal autoantibodies of interest.
Eight studies met the inclusion criteria [9, 19, 28–33]. 
However, one study [9] was subsequently excluded due 
to having an overlapping sample with a larger study [30]. 
A second study examined α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptor (AMPAR) antibodies 
Studies identified in search databases 




Records screened (titles and abstracts) 
(n=329)
Full text articles assessed for 
eligibility (n=17)
Case reports (n=40)
Studies in animals and cell cultures (n=176)
Duplicate not removed by OVID (n=29)
Excluded for other reasons (n=67)
Included in qualitative synthesis 
(n=8)
Included in meta-analysis (n=6)
Only Ab +ve participants recruited (n=2)
Poorly defined dementia group (n=2)
Dementia seropositivity not reported (n=2)
Did not have dementia syndrome (n=1)
Neuronal antibodies of interest not tested (n=1)
Review (n=1)
NMDAR antibody assay not performed (n=1)
Overlap in study cohorts (n=1)
Fig. 1  Search process
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only [28] and so was excluded from the meta-analyses. Six 
remaining studies examined NMDAR antibodies and were 
included in the meta-analysis [19, 29–33].
Study characteristics
Sample size, demographic factors, and group status
Across the six studies, we included 678 individuals with 
a typical dementia disease, including Alzheimer’s disease, 
frontotemporal dementia, vascular dementia, dementia with 
Lewy bodies, Parkinson’s disease dementia and progressive 
supranuclear palsy, 520 healthy controls, and 70 participants 
with an atypical dementia. Gender and age distribution were 
not reported in all studies. Demographic information is 
shown in Table 1.
All studies recruited patients with clinical diagnoses of 
dementia; four of these confirmed diagnoses with clinical 
testing, including neuropsychological assessments and MRI 
[29–31, 33]. Three studies excluded patients with possibly 
confounding co-morbidities (e.g., infection, autoimmune 
disease, and cancer) [29–31]. One study recorded the prev-
alence of autoimmune disease and cancer in their cohort, 
but did not exclude these patients from the typical dementia 
group [32]. One study did not describe any confirmatory 
tests for dementia diagnoses or assessment for co-morbid-
ities [19].
Four studies reported antibody prevalence in atypical 
dementia, i.e., patients characterised by symptoms or pathol-
ogy that are not common to typical dementia syndromes [19, 
29, 31, 32]. Two studies identified atypical cases through 
efforts to confirm dementia diagnoses among the recruited 
participants, and subsequently excluded these individuals 
from the typical dementia groups [29, 31]. Two other stud-
ies included targeted-recruitment of patients with atypical 
dementia [19, 32]. Atypical features in these cases included 
atypical onset or progression (presenile onset, rapid progres-
sion, subacute onset, atypical onset, partial regression, or 
plateau), CSF abnormalities (oligoclonal bands, pleocyto-
sis, blood–brain-barrier dysfunction, or raised protein), and 
‘immune challenge’ (autoimmune disease, cancer, or current 
infection). In the present analysis, these participants could 
not be classified under a typical dementia syndrome and 
were included as a heterogenous ‘atypical’ dementia group.
Not all studies described the recruitment process for 
healthy controls. Studies that did so excluded patients with 
neurodegenerative disorders [29], neurological or psychiat-
ric disease [30], self-reported neuropsychiatric disease [33], 
or all of these [32]. One study specified exclusion of those 
with abnormalities in routine laboratory tests [31].
Antibody assays
Serum was collected from patients and healthy controls in 
all studies. Four of the six studies also collected CSF sam-
ples and three studies tested NMDAR antibodies in CSF. A 
few patients across studies were found to have positive CSF 
NMDAR antibodies, 12 in total (see Table 1) and only one 
study reported data with CSF and serum results matched 
for patients [19]. To increase statistical power, the present 
analysis only considered anti-NMDAR assays in serum. 
All studies used recombinant cell-based indirect immuno-
fluorescence using fixed transfected HEK293 cells to detect 
anti-NMDAR antibodies, using non-transfected cells as 
negative controls. Non-NMDAR antigens were also inves-
tigated using various methods. Antigens included: GAD65, 
LGI1, CASPR2, AMPAR, and  GABABR [19, 31] and non-
specified targets [33]. Four studies described blinded assays 
or analysis [29, 30, 32, 33]. Only NMDAR antibody assays 
were considered for meta-analysis; three studies reported 
results for IgG, IgA, and IgM [29, 30, 32], one reported IgA 
and IgM [33], one reported IgG only [31], and one reported 
IgA only [19].
Study‑quality assessment
Study-quality ratings are provided in Table 2. Mean total 
quality score was 5.33 (out of a possible 12) and range was 
0–8. Studies were awarded a point for sample size when 
a calculation to determine the appropriate sample size 
was performed. Where a sample size calculation was not 
described, we considered the overall prevalence of anti-
neuronal autoantibodies in the population (approx. 5% in 
healthy and approx. 10% in disease groups [34]). We speci-
fied that five positive individuals in each group would per-
mit a meaningful comparison, so group sizes of 100 healthy 
and 50 dementia were required to award a point. Studies 
that examined a total population (e.g., using health records) 
and included a large sample size were also awarded a point. 
Sample size was inadequate in two studies [19, 31]. Four 
of the six studies adequately defined and confirmed typical 
dementia diagnoses in cases [29, 30, 32, 33], but only one 
of these studies recruited a sample that was considered to 
be representative of the target population [33]. One other 
study recruited dementia cases that were likely representa-
tive, but the authors did not describe any attempt to confirm 
dementia diagnoses [32]. A few studies described recruit-
ment of controls or commented on the extent to which these 
individuals were representative of the general population. 
Controls were representative of the general population in 
only one study [33].
Cases and controls were age matched in four studies 
[29, 31–33], and were also gender matched in one study 
[33]. Two studies failed to confirm that controls did not 
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have exposures that might influence antibody prevalence 
(e.g., infection, autoimmune disease, immunosuppression, 
or cancer) [19, 31]. For antibody assays, all studies used 
an established method for determining seropositivity (i.e., 
cell-based assay) in cases and controls, but only four of 
the six studies described a blinded protocol, and serum 
dilutions were not reported in all studies. Two studies 
described assays for which no results were reported (for 
IgG NMDAR antibodies and for non-NMDAR antigens) 
[19, 33]. Response rate, which reflects the proportion of 
individuals who were invited to participate in the study 
and then agreed, was not reported for cases or controls in 
any study.
Meta‑analysis of frequency of IgG and IgA or IgM 
NMDAR antibodies
IgG NMDAR antibodies in dementia vs healthy 
age‑matched controls
Results of meta-analyses are provided in Table 3. When 
examining dementia of any type (typical and atypical 
Table 1  Demographics for patients and healthy controls from studies included in the meta-analysis
AD Alzheimer’s disease, VD vascular dementia, FTD frontotemporal dementia, DLB dementia with Lewy bodies, PPA primary progressive apha-
sia, PDD Parkinson’s disease dementia, PSP progressive supranuclear palsy







M F Mean ± SD
Busse et al. [28] Typical dementia AD classical 145 6 (4) 0 45 100 81
VD 61 10 (16) 0 20 41 78
FTD 34 3 (9) 0 14 20 77
Control Healthy 32 2 (6) 0 8 24 72
Atypical dementia Non-classical AD 11 11 (100) 0 5 6 81
Busse et al. [9] Typical dementia AD 46 4 (9) – 16 30 80
VD 26 4 (15) – 10 16 74
FTD 18 4 (22) – 7 11 79
DLB 11 1 (9) – 6 5 76
Control Healthy 21 2 (10) – 9 12 72
Coban et al. [30] Typical dementia AD classical 28 0 – – – –
FTD classical 6 0 – – – –
Control Healthy 50 0 – 25 25 53 ± 16
Atypical dementia AD with atypical features 11 0 – – – –
FTD with atypical features 4 0 – – – –
DLB with atypical features 1 1 (100) – 1 0 58
Doss et al. [31] Typical dementia AD 100 10 (10) 1 (1) – – 70
VD 30 0 1 (3) – – –
FTD (inc PPA) 65 9 (14) 3 (5) – – –
PDD 25 5 (20) 0
LBD 11 2 (18) 0 – – –
PSP 11 6 (55) 0 – – –
Control Healthy 47 2 (4) 0 – – 67
Atypical dementia Unclassifiable dementia 20 12 (60) 4 (20) – – –
Pruss et al. [19] Typical dementia AD 10 0 0 – – –
FTD 9 1 (11) 1 (11) – – –
DLB 10 0 0 – – –
Control Healthy 75 0 0 – – –
Atypical dementia Progressive cognitive 
decline
23 6 (26) 2 (9) 8 15 –
Hopfner et al. [32] Typical dementia PDD 32 4 (13) – 20 12 73 ± 6
Control Healthy 295 65 (22) – 185 110 66 ± 6
Total typical dementia 678 69 (11) 6/511 (1)
Total atypical dementia 70 30 (43) 6/54 (11)
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groups combined), a random-effects model indicated no 
significant association between presence of IgG NMDAR 
antibodies and dementia status [OR = 1.05 (95% CI: 0.20 
to 5.36), p = 0.957]. When analyses were performed sepa-
rately for each dementia type, there was no significant asso-
ciation found between IgG NMDAR antibody presence and 
typical dementia status [OR = 0.72, (95% CI: 0.13 to 4.04), 
p = 0.710]. There was, however, an association found in the 
analysis restricted to atypical dementia types [OR = 8.09 
(95% CI: 1.51 to 56.85), p = 0.036] (see Fig. 2). Heteroge-
neity estimates for all three analyses were small (I2 = 0.0%) 
and not statistically significant (p for Cochran’s Q > 0.05). 
IgA or IgM NMDAR antibodies in dementia vs healthy 
age‑matched controls
A random-effects model also indicated no significant dif-
ference in the prevalence of IgA or IgM NMDAR antibod-
ies between all dementia cases (typical and atypical) and 
healthy individuals, [OR = 1.93 (95% CI: 0.67 to 5.60), 
p = 0.227) or between typical dementia and healthy indi-
viduals [OR = 1.30 (95% CI: 0.58 to 2.90), p = 0.526] (see 
Table 3). However, there was a significantly higher preva-
lence of IgM or IgA NMDAR antibodies in atypical demen-
tia when compared to healthy individuals [OR = 42.48 (95% 
CI: 11.39 to 158.52), p < 0.001] (see Fig. 3). The heterogene-
ity estimate for atypical dementia was low (I2 = 0.4%, p for 
Cochran’s Q = 0.366). Greater heterogeneity was seen for 
the all dementia and typical dementia analyses, but this did 
not reach statistical significance (I2 = 57.3%, p for Cochran’s 
Q = 0.053; I2 = 25.6%, p for Cochran’s Q = 0.251).
Meta‑regression of study‑quality score on effect size
Exploratory meta-regression analyses were performed to 
examine whether effect sizes were associated with study 
quality (NOS scores). No significant association was found 
in any of the six analyses.
Discussion
This is the first systematic review and meta-analysis to inves-
tigate an association between NMDAR antibody seropositiv-
ity and primary dementia syndromes. Overall, no association 
was found between the presence of IgG or IgA/IgM serum 
NMDAR antibodies and dementia in typical dementias or 
when all dementia types were combined. However, when 
individuals with ‘atypical dementia’ were considered sepa-
rately, both IgG and IgA/IgM NMDAR antibodies were sig-
nificantly more common in patients than healthy controls.
We note a number of issues which necessitate caution 
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intervals are seen for all effect sizes and particularly for 
atypical dementia, due to the small-sample sizes of the 
individual studies. Furthermore, many of the included 
studies in this meta-analysis do not make explicit whether 
the ‘atypical’ criteria were defined prospectively. If this 
description was applied post hoc, the bias introduced 
would undermine the validity of the findings.
In addition, the description of atypical dementia was 
not universally applied across studies and it is possible that 
differences in this definition underlie much of the variation 
in antibody prevalence between the studies. Such defini-
tions are prone to circularity (e.g., the presence of oligo-
clonal bands or serum NMDAR antibodies may lead a cli-
nician to call this dementia syndrome ‘atypical’), although 
in most cases, there was additional evidence to suggest 
that the dementia syndrome was not typical.
There was a degree of heterogeneity in the description 
of ‘atypical’ dementia despite consensus across studies that 
these patients did not meet the full criteria for established 
dementia syndromes. Busse and colleagues defined ‘atypi-
cal’ dementia as patients without the imaging or CSF abnor-
malities characteristic of Alzheimer’s disease (i.e., minimal 
or no hippocampal atrophy or normal CSF Tau and B-amy-
loid) [29]. They also noted poorer prognostic outcomes and 
minimal symptomatic response to the usual cholinesterase 
inhibitor treatment in atypical dementia patients. Two stud-
ies established higher rates of CSF abnormalities within the 
‘atypical’ group, with subacute onset and rapid symptomatic 
Table 3  Meta-analyses 
comparing frequency of 
NMDAR antibody among 
dementia patients and healthy 
controls
OR odds ratio, CI confidence interval, Q Cochran’s Q to detect statistically significant heterogeneity, 
p < 0.05 indicates significant heterogeneity, I2 variation in OR attributable to heterogeneity
Bold indicates statistical significance at the 0.05 level (two-tailed)
No. studies Total N 
dementia/
control
OR 95% CI P P for Q I2 (%)
IgG NMDAR antibody
 All-case dementia 4 664/150 1.05 0.20–5.36 0.957 0.616 0.0
 Typical dementia 4 617/150 0.72 0.13–4.04 0.710 0.799 0.0
 Atypical dementia 3 47/129 8.09 1.51–56.85 0.036 0.832 0.0
IgM or IgA NMDAR antibody
 All-case dementia 5 698/470 1.93 (0.67–5.60) 0.227 0.053 57.3
 Typical dementia 5 644/470 1.30 (0.58–2.90) 0.526 0.251 25.6
 Atypical dementia 3 54/154 42.48 (11.39–158.52)  < 0.001 0.366 0.4
Fig. 2  Meta-analysis of IgG NMDAR antibody in atypical dementia vs controls
2776 Journal of Neurology (2021) 268:2769–2779
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progression [31, 32]. Doss and colleagues also noted higher 
rates of so-called ‘immune challenges’ including autoim-
munity amongst the ‘atypical’ group [32].
Notable similarities exist between the description of the 
‘atypical’ dementias and NMDAR encephalitis itself, and so, 
the increased prevalence of NMDAR antibodies within this 
patient group is not unexpected [35]. Demographic differ-
ences are known to influence presentation in anti-NMDAR 
encephalitis, and thus, it seems possible that, in older adults, 
NMDAR antibodies could cause an attenuated encephalitic 
syndrome more closely resembling a neurodegenerative 
dementing process or an ‘autoimmune dementia’ [36, 37]. 
Indeed, numerous reports illustrate cases where antibody-
mediated cognitive impairment is initially diagnosed as 
primary neurodegenerative dementias, and also evidence 
the positive outcomes when immunotherapy treatment is 
introduced [16–19, 31, 37]. This raises the possibility that 
autoimmune dementia could be considered where ‘atypical’ 
dementia, which does not meet the criteria for established 
dementia syndromes, is seen.
Previous studies that have sought to demonstrate the 
validity of the ‘autoimmune dementia’ concept have 
included patients due to clinical suspicion or confirmation of 
autoimmune encephalopathy rather than those chosen from 
an unselected dementia cohort [17], cementing the notion 
that autoimmune encephalitis can present with a dementia-
predominant picture. Notably, in one such study, dementia 
was present in isolation in only 29% of an ‘autoimmune 
dementia’ cohort, with the occurrence of other neurologi-
cal features occurring in the majority [17]. It is not clear 
whether or to what extent this category may overlap with 
the ‘atypical dementia’ category described in the present 
review, but the phenomenon of autoimmune dementia could 
be akin to the antibody-mediated syndromes described in 
autoimmune psychosis and autoimmune epilepsy [38, 39].
A causative link between NMDAR antibodies and atypi-
cal dementia has yet to be shown, but given the reversible 
nature of autoantibody-mediated processes, further inves-
tigation is warranted. We feel that it will be important for 
future studies to systematically and prospectively define the 
clinical features which indicate that NMDAR antibodies may 
contribute to the clinical symptoms, as well as address the 
described limitations.
In contrast, in established dementia syndromes such as 
Alzheimer’s dementia and Parkinson’s disease dementia 
where the prevalence of NMDAR antibodies was not found 
to be elevated, it seems less likely that they play a significant 
role in the pathogenesis. However, in Alzheimer’s disease 
and vascular dementia, NMDAR antibodies have been found 
to associate with psychiatric symptoms (particularly psycho-
sis), suggesting that these antibodies could be biomarkers of 
neuropsychiatric symptoms in dementia even if they are not 
primarily pathogenic [9]. While Doss et al. did not replicate 
the association between NMDAR antibodies and neuropsy-
chiatric symptoms in dementia, theirs was a cruder estimate 
looking at neuropsychiatric symptoms collectively without 
distinguishing psychotic symptoms from others [32]. None-
theless, these findings also merit further investigation.
Consideration should also be given to the emerging 
notion that in some circumstances, NMDAR antibodies may 
have a role as endogenous NMDAR antagonists and hence 
have a protective function [40]: the possibility that in some 
Fig. 3  Meta-analysis of IgA or IgM NMDAR antibody in atypical dementia vs controls
2777Journal of Neurology (2021) 268:2769–2779 
1 3
cases dementia, serum NMDAR antibodies could represent 
an adaptive physiological response, potentially even amelio-
rating clinical severity, is challenging but requires systematic 
evaluation.
IgG vs IgA/IgM NMDAR antibody
We had anticipated a distinction seen in the prevalence of 
IgG NMDAR antibodies and IgA or IgM NMDAR iso-
types in dementia. IgG antibodies to the NR1 subunit of the 
NMDAR are recognised to be encephalitogenic, but the role 
of IgA and IgM NMDAR antibodies is less clear.
However, all NMDAR antibody isotypes have been found 
to have pathogenic potential, causing a reduction in the den-
sity of NMDARs with subsequent decreases in NMDAR-
mediated currents [20]. Clinically, IgA NMDAR antibodies 
have been associated with a slowly progressive cognitive 
impairment, closer to a dementia phenotype but apparently 
reversible with immunotherapy [19]. Furthermore, non-IgG 
NMDAR antibodies have been implicated in the cognitive 
impairment seen in a range of disorders outside of encepha-
litis. IgA and IgM NMDAR antibodies are detected in cancer 
and in stroke at twice the frequency of IgG antibodies, with 
the cognitive impairment closely correlated to antibody titre 
in cancer [29, 41, 42].
While our results show greater prevalence of NMDAR 
antibodies in atypical dementia, no variation was seen across 
the antibody isotypes. It may be that any clinical variation 
is not picked up by the heterogeneous category of ‘atypical 
dementia’ and future studies should aim to define this clini-
cal population more closely.
Findings from systematic review
Although heterogeneity estimates were not statistically sig-
nificant, our systematic review demonstrated substantial 
methodological variation between studies. The quality of 
included studies was moderate, with a mean rating of only 
5.3 (12 representing the total maximum score). In particu-
lar, there was one outlier (which scored 0 overall) which 
contributed to the overall low mean score for quality [19]. 
Two of the studies did not match groups demographically, a 
major confounding factor given the prevalence of NMDAR 
antibodies is known to increase with age. Furthermore, 
no study was adequately powered to detect differences in 
frequency of NMDAR antibodies with most studies only 
reaching adequate sample size for either patients or con-
trols. Only one study ensured representativeness of cases 
and controls which limits the extent to which sampling bias 
can be assessed. While there was no measure that all stud-
ies universally achieved, most studies had an independent 
blinded assay for the measurement of NMDAR antibodies.
Limitations
While this is the first systematic review and meta-analysis 
to investigate the prevalence of neuronal autoantibodies in 
dementia syndromes, a number of issues limit the scope 
of conclusions drawn.
The strict methodology and small number of stud-
ies available for meta-analysis increase the risk of type 
II error. Our finding of no association between serum 
NMDAR antibodies and dementia in either typical 
dementias or all dementia types combined could poten-
tially represent a false-negative result. Due to the small 
numbers of studies available, analyses were only possi-
ble for NMDAR antibodies. One study was identified in 
the systematic review aiming to identify the prevalence 
of AMPAR antibodies, but in the absence of any others, 
it was excluded. However, it could be that the paucity of 
studies is explained by the relatively low prevalence of 
these autoantibodies in dementia syndromes, as is alluded 
to by Hopfner and colleagues who did not include analyses 
for other tested antibodies due to their low prevalence [33].
We only included serum NMDAR antibodies in our meta-
analysis. However, increasingly, CSF autoantibodies are felt 
to be required for definitive diagnosis of most autoimmune 
encephalitis subtypes. This requirement reflects the prob-
lem of nonspecificity of many serum-only autoantibodies, 
i.e., the need to avoid false-positive diagnoses in the con-
text of elevated rates of such antibodies detected in healthy 
populations or disease controls (where their significance is 
uncertain), as well as the notion that intrathecal antibody 
synthesis is necessary (and probably sufficient) for enceph-
alitis pathogenesis [43]. Only three of the included stud-
ies tested NMDAR antibodies in the CSF of patients and 
few had a positive NMDAR antibody (12 positives overall; 
2% NMDAR antibody positive of CSF tested patients with 
dementia vs 13% of NMDAR antibody seropositive patients 
with dementia). However, given the smaller patient num-
bers undergoing NMDAR antibody CSF testing, it is difficult 
to interpret this finding further. Future studies should look 
to simultaneously test both serum and CSF for NMDAR 
antibodies. Furthermore, future studies should incorporate 
paraclinical testing including EEG and MRI, since abnor-
malities in these modalities may provide further support for 
an antibody’s pathogenicity.
The small number of studies also prevented more robust 
analyses comparing effect sizes across individual groups. 
Due to insufficient numbers, we were not able to separate out 
dementia subtypes and instead grouped patients into ‘typi-
cal’ or ‘atypical’ syndromes. Thus, we cannot be specific as 
to any differences in NMDAR antibody frequencies between 
dementia subtypes and given the different aetiologies and 
clinical presentations underpinning respective dementia 
subtypes, this is a major limitation. Furthermore, due to the 
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small sample-sizes tested, large confidence intervals are seen 
for the autoantibody frequencies within atypical dementias.
Conclusions and recommendations
We did not find evidence to suggest NMDAR antibodies are 
more common in AD or other dementia-related diseases than 
in healthy controls. However, both IgG and IgM or IgA 
NMDAR serum antibodies were found to be more common 
in ‘atypical’ dementia vs healthy controls. Due to the meth-
odological issues described, we advise caution interpreting 
this result and suggest that further investigation is warranted. 
Only three of the included studies examined patients with 
atypical dementia and in each, due to the small-sample sizes, 
the confidence intervals were extremely wide.
This meta-analysis supports the need for additional, 
methodologically robust studies to investigate an associa-
tion between NMDAR antibodies and dementia. To improve 
study quality and reduce the risk of bias, we recommend 
future studies include larger sample sizes, measure antibod-
ies in CSF and serum, aim to apply a consistent, prospective 
definition to patients with ‘atypical’ dementia, and endeav-
our to match groups on confounders such as age and gender 
to allow more robust analyses. In particular, future research 
would benefit from a larger, prospective study to determine 
the prevalence of NMDAR antibodies in ‘atypical’ dementia.
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